ASP Isotopes Inc. (ASPI)

NASDAQ: ASPI · IEX Real-Time Price · USD
2.03
-0.08 (-4.03%)
At close: Dec 1, 2022 4:00 PM
2.08
+0.06 (2.72%)
Pre-market: Dec 2, 2022 4:05 AM EST

Company Description

ASP Isotopes is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries.

We have an exclusive license to use proprietary technology, the Aerodynamic Separation Process (“ASP technology”), originally developed and licensed to us by Klydon Proprietary, for the production, distribution, marketing and sale of all isotopes.

Our initial focus is on the production and commercialization of enriched Molybdenum-100 (“Mo-100”). Klydon has agreed to provide us a first commercial-scale Mo-100 enrichment plant located in South Africa with a manufacturing capacity of 20 kg/year of 95% enriched Mo-100 when fully operational.

We believe that the Mo-100 we may develop using the ASP technology has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry.

We also intend to use the ASP technology licensed to us by Klydon to produce enriched Uranium-235 (“U-235”).

We believe that the U-235 we may develop using the ASP technology may be commercialized as a nuclear fuel component for use in the new generation of HALEU-fueled small modular reactors that are now under development for commercial and government uses.

ASP Isotopes Inc.
ASP Isotopes logo
Country United States
Founded 2021
IPO Date Nov 10, 2022
Industry Materials
Sector Chemicals
Employees 4
CEO Paul E. Mann

Contact Details

Address:
433 Plaza Real, Suite 275
Boca Raton, FL 33432
United States
Phone (561) 709-3034
Website aspisotopes.com

Stock Details

Ticker Symbol ASPI
Exchange NASDAQ
Fiscal Year End December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001921865
Employer ID 87-2618235
SIC Code 2890

Key Executives

Name Position
Paul E. Mann Chairman and Chief Executive Officer
Hendrik Strydom, Ph.D. Chief Technology Officer and Director
Robert Ainscow Interim Chief Financial Officer
Joshua Donfeld Director
Duncan Moore, Ph.D. Director
Sergey Vasnetsov Director
Todd Wider, M.D. Director

Latest SEC Filings

Date Type Title
Nov 29, 2022 8-K Current Report
Nov 16, 2022 S-8 Securities to be offered to employees in employee benefit plans
Nov 16, 2022 8-K Current Report
Nov 14, 2022 424B4 Prospectus
Nov 10, 2022 CERT Certification by an exchange approving securities for listing
Nov 9, 2022 EFFECT Notice of Effectiveness
Nov 9, 2022 8-A12B Registration of securities
Nov 9, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Nov 4, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Oct 31, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933